Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583081 | 0.81 | CCNE2 (0.44) | NPSR1CYP2D6TDP1LMNATSHR | |
| SCHEMBL1162021 | 0.79 | NPSR1 (0.62) | NPSR1CYP2D6CYP1A2CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL17710397 | 0.79 | CCNE2 (0.42) | NPSR1CYP2D6TDP1LMNATSHR | |
| SCHEMBL4551365 | 0.79 | POLB (0.48) | NPSR1CYP2D6TDP1LMNATSHR | |
| SCHEMBL11691246 | 0.79 | NPSR1 (0.41) | NPSR1CYP2D6TDP1LMNATSHR | |
| SCHEMBL1453847 | 0.77 | GAA (0.43) | NPSR1CYP2D6TDP1LMNATSHR | |
| SCHEMBL3162604 | 0.77 | KIF11 (0.43) | CYP1A2CYP3A4LMNATSHRCYP2C19 | |
| SCHEMBL5699071 | 0.75 | PDK1 (0.44) | NPSR1CYP2D6CYP1A2CYP3A4TDP1 | |
| SCHEMBL8433637 | 0.74 | TDP1 (0.39) | TAAR1NPSR1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL23957785 | 0.74 | TAAR1 (0.42) | TAAR1NPSR1CYP2D6CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101273016-B | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV | 2013-01-02 | — | — | CN | claimed |
| CN-101273016-A | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | CN | claimed |
| CN-1665807-B | Physiologically active substance | MICROBIOPHARM JAPAN CO LTD | 2013-09-11 | — | — | CN | disclosed |
| CN-101273016-B | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV | 2013-01-02 | — | — | CN | disclosed |
| US-8268827-B2 | Pyridazinone derivatives as PARP inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-09-18 | — | — | US | disclosed |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA S.R.L. (IT) | 2010-10-14 | — | — | US | disclosed |
| EP-2220073-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-08-25 | — | — | EP | disclosed |
| CN-101730693-A | Process for producing macrolide compound and production intermediate thereof | EISAI R&D MAN CO LTD | 2010-06-09 | — | — | CN | disclosed |
| CN-1671856-B | Novel physiologically active substances | EISAI R&D MAN CO LTD | 2010-05-12 | — | — | CN | disclosed |
| CN-101663296-A | 12-membered ring macrolactam derivatives | EISAI R&D MAN CO LTD | 2010-03-03 | — | — | CN | disclosed |
| WO-2009063244-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-05-22 | — | — | WO | disclosed |
| CN-1671856-A | Novel physiologically active substances | MERCIAN CORP (JP) | 2005-09-21 | — | — | CN | disclosed |
| CN-1665807-A | Novel physiolgically active substances | MERCIAN CORP (JP) | 2005-09-07 | — | — | CN | disclosed |
| EP-0266558-A2 | 5-Alkylbenzimidazoles, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1988-05-11 | — | — | EP | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
| EP-0020401-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 1,4-DIAZA-2-CYCLOALKANONE AND SUBSTITUTED DERIVATIVES THEREOF. | GOODRICH CO B F (US) | 1981-01-07 | — | — | EP | disclosed |
| EP-0020401-A4 | IMPROVED PROCESS FOR THE SYNTHESIS OF 1,4-DIAZA-2-CYCLOALKANONE AND SUBSTITUTED DERIVATIVES THEREOF. | GOODRICH CO B F (US) | 1980-08-11 | — | — | EP | disclosed |
| WO-1980000702-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 1,4-DIAZA-2-CYCLOALKANONE AND SUBSTITUTED DERIVATIVES THEREOF | GOODRICH CO B F (US) | 1980-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | TAAR1 4229/4885NPSR1 4377/4885CYP2D6 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.